低剂量促红细胞生成素-β可改善贫血并维持慢性丙型肝炎患者接受利巴韦林联合聚乙二醇干扰素α-2b 联合治疗时的利巴韦林剂量。

Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b.

机构信息

Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital.

出版信息

Hepatol Res. 2009 Jun;39(6):539-45. doi: 10.1111/j.1872-034X.2009.00489.x. Epub 2009 Feb 25.

DOI:10.1111/j.1872-034X.2009.00489.x

PMID:19254345

Abstract

AIM

Anemia during combination therapy with pegylated interferon alfa-2b plus ribavirin (RBV) for chronic hepatitis C virus (HCV) patients usually leads to RBV dose reduction or discontinuation. This study evaluated the effect of erythropoietin-beta (EPO-beta) to maintain RBV dose and hemoglobin (Hb) level in chronic HCV patients treated with antiviral combination therapy.

METHODS

Eighty-eight chronic HCV patients who developed anemia during therapy were enrolled into this retrospective study: 55 in the EPO-beta group and 33 in the untreated group. The study endpoints were to assess the RBV maintenance and the changes in Hb.

RESULTS

A higher percentage of patients with RBV maintenance was observed in the EPO-beta group compared with the untreated group (nadir Hb level <10.5 g/dL; 70% vs. 38%, P = 0.020; nadir Hb < 10 g/dL; 62% vs. 27%, P = 0.046). The mean Hb change from week 12 to week 20 was higher in the EPO-beta group when compared with the untreated group, especially for patients receiving a total EPO-beta dose of more than 16 000 U (+0.70 g/dL vs. -0.32 g/dL, P = 0.023) and of 10 000 U-14 000 U (+0.60 g/dL vs. -0.32 g/dL, P = 0.023).

CONCLUSIONS

Low-dose EPO-beta can maintain RBV dose and increase Hb levels in anemic chronic HCV patients receiving combination therapy.

摘要

目的

聚乙二醇干扰素 alfa-2b 联合利巴韦林（RBV）治疗慢性丙型肝炎病毒（HCV）患者时发生的贫血通常导致 RBV 剂量减少或停药。本研究评估了促红细胞生成素-β（EPO-β）在接受抗病毒联合治疗的慢性 HCV 患者中维持 RBV 剂量和血红蛋白（Hb）水平的效果。

方法

本回顾性研究纳入了 88 例在治疗过程中发生贫血的慢性 HCV 患者：EPO-β 组 55 例，未治疗组 33 例。研究终点为评估 RBV 维持和 Hb 变化。

结果

EPO-β 组维持 RBV 的患者比例高于未治疗组（Hb 最低值<10.5 g/dL；70%比 38%，P = 0.020；Hb 最低值<10 g/dL；62%比 27%，P = 0.046）。与未治疗组相比，EPO-β 组从第 12 周到第 20 周的平均 Hb 变化更高，尤其是接受总 EPO-β 剂量超过 16 000 U 的患者（+0.70 g/dL 比-0.32 g/dL，P = 0.023）和 10 000 U-14 000 U 的患者（+0.60 g/dL 比-0.32 g/dL，P = 0.023）。